Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases,Angewandte Chemie International Edition

当前位置： X-MOL 学术 › Angew. Chem. Int. Ed. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases
Angewandte Chemie International Edition ( IF 16.1 ) Pub Date : 2024-09-14 , DOI: 10.1002/anie.202411037
Liang Ouyang ₁ , Wen Shuai ₂ , Panpan Yang ₂ , Huan Xiao ₂ , Yumeng Zhu ₂ , Faqian Bu ₂ , Aoxue Wang ₂ , Qiu Sun ₂ , Guan Wang ₃

Affiliation

We discovered JC16I, the first JNK3-selective covalent inhibitor, which could target conserved cysteine in JNK family. JC16I potently and selectively inhibits and labels JNK3 in living cells and cell lysates, and demonstrates neuroprotective effects in PD models without compromising safety.

中文翻译：

小分子选择性共价抑制 JNK3 治疗帕金森病

我们发现了 JC16I，第一个 JNK3 选择性共价抑制剂，它可以靶向 JNK 家族中保守的半胱氨酸。JC16I 有效、选择性地抑制和标记活细胞和细胞裂解物中的 JNK3，并在 PD 模型中表现出神经保护作用，而不会影响安全性。

更新日期：2024-09-14

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南